Related Experiment Video
Updated: Jul 15, 2026
Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
Published on: July 30, 2016
Evidence-based management for preeclampsia
Peter von Dadelszen1, Jennifer Menzies, Sarah Gilgoff
1Department of Obstetrics and Gynaecology, University of British Columbia and British Columbia Reproductive Care Program, Provincial Health Services Authority, Vancouver, BC, Canada. pvd@cw.bc.ca
Insights
Preeclampsia is a systemic disorder affecting multiple organs. Comprehensive maternal and fetal surveillance, timely antihypertensive treatment, and magnesium sulfate for eclampsia are crucial for managing this condition and preventing long-term cardiovascular risks.
Area of Science:
- Obstetrics and Gynecology
- Maternal-Fetal Medicine
- Nephrology
Background:
- Preeclampsia is a complex systemic disorder with variable clinical presentations.
- It affects multiple maternal organ systems and the fetus, necessitating a comprehensive management approach.
Purpose of the Study:
- To review the systemic nature of preeclampsia and provide recommendations for evaluating and managing associated organ dysfunction.
- To outline current guidelines for antihypertensive treatment, eclampsia prophylaxis, and fluid management.
- To highlight the long-term cardiovascular risks associated with early-onset or severe preeclampsia.
Main Methods:
- Systematic review of current literature and clinical guidelines on preeclampsia management.
- Analysis of diagnostic criteria and therapeutic interventions for maternal organ dysfunction.
- Evaluation of evidence for expectant management in remote-term preeclampsia and long-term cardiovascular risk prediction.
Main Results:
- Preeclampsia affects multiple organ systems, requiring thorough maternal and fetal surveillance.
- Expectant management for preeclampsia remote from term (<34 weeks) improves perinatal outcomes but demands rigorous maternal monitoring.
- Specific antihypertensive medications (Methyldopa, Labetalol, Nifedipine) are recommended, with certain drugs to avoid (ACE inhibitors, ARBs, atenolol).
- Magnesium sulfate (MgSO4) is indicated for eclampsia prophylaxis and treatment.
- Fluid management guidelines emphasize limiting intake and tolerating low urine output.
- Early-onset or severe preeclampsia is linked to future cardiovascular morbidity and mortality.
Conclusions:
- Preeclampsia requires a holistic management strategy addressing systemic involvement and potential organ dysfunction.
- Timely initiation of antihypertensive therapy and appropriate use of magnesium sulfate are critical for maternal and fetal well-being.
- Women with early-onset or severe preeclampsia should be considered for long-term cardiovascular risk screening and intervention.
Abstract:
This review reflects both the variable presentation and the systemic nature of preeclampsia. Recommendations for the comprehensive evaluation and management of organ dysfunction associated with pre-eclampsia are included. The main points in the review are that: (1) Preeclampsia is a systemic disorder that may affect many organ systems. (2) For preeclampsia remote from term (<34 weeks), expectant management improves perinatal outcomes, but requires obsessive surveillance to mitigate maternal risks and is a "package." (3) Initial assessment and ongoing surveillance of women with preeclampsia should include assessment of all vulnerable maternal organs as well as of the fetus. (4) Initiate antihypertensive drug treatment immediately if sBP >160 mmHg or dBP more than 110 mmHg, or if sBP 140-159 mmHg and/or dBP 85-109 mmHg (prepregnancy renal disease or diabetes). (5) The treatment of nonsevere pregnancy hypertension should include a treatment goal of dBP 80-105 mmHg (depending on practitioner preference), with one of the following agents, Methyldopa, Labetalol, Nifedipine, or, with special indications (renal or cardiac diseases), diuretics. (6) Drugs to avoid: angiotensin-converting enzyme inhibitors; angiotensin II receptor antagonists; and atenolol. (7) For the acute management of severe hypertension, initially reduce dBP by 10 mmHg and maintain the blood pressure at or below that level with either Nifedipine or Labetalol. (8) For both prophylaxis against and treatment of eclampsia, MgSO4 (4 g IV stat, then 1 g/hr). (9) For recurrent seizures, MgSO4 (2g IV stat, then increase to 1.5 g/hr). (10) Total fluid intake should not exceed 80 ml/hr; tolerate urine outputs as low as 10 ml/hr. (11) Early-onset and/or severe preeclampsia predict later cardiovascular morbidity and mortality; it would seem prudent to offer such women screening and lipid lowering interventions.
Related Concept Videos
01:23Hypertension V: Nursing Management
01:19Mitral Valve Prolapse III: Nursing Management
01:26Nephrotic Syndrome II : Assessment and Medical Management
01:24Nephrotic Syndrome III : Nursing Management
01:25Errors occurring during blood pressure monitoring
Several factors...
01:10Pre-Procedural Guidelines for Assessing Blood Pressure